Effectiveness and cost-effectiveness of diabetes prevention among adherent participants

American Journal of Managed Care

Volumn 19, Issue 3, 2013, Pages 194-202

  Herman, William H ^a   Edelstein, Sharon L ^b   Ratner, Robert E ^c   Montez, Maria G ^d   Ackermann, Ronald T ^e   Orchard, Trevor J ^f   Foulkes, Mary A ^b   Zhang, Ping ^g   Saudek, Christopher D ⁱ   Brown, Morton B ^h  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FOLLOW UP; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; WEIGHT REDUCTION;

AGED; BLOOD GLUCOSE; COST SAVINGS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84877729979     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686.
2. The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723-730.
3. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle modification or metformin. N Engl J Med. 2002;346(6):393-403.
4. Hoerger TJ, Hicks KA, Sorensen SW, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care. 2007;30(11):2874-2879. (Pubitemid 350083138)
5. Tabaei BP, Engelgau MM, Herman WH. A multivariate logistic regression equation to screen for dysglycemia: development and validation [published correction appears in Diabetic Med. 2006;23:221]. Diabetic Med. 22:599-605.
6. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39(3):298-305. (Pubitemid 26066801)
7. Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165-2171.
8. Venditti EM, Bray GA, Carrion-Petersen ML, et al; the Diabetes Prevention Program Research Group. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes (Lond). 2008;32(10):1537-1544.
9. Kingsley RG, Wilson GT. Behavior therapy for obesity: a comparative investigation of long-term efficacy. J Consult Clin Psychol. 1977;45(2):288-298. (Pubitemid 8062206)
10. Renjilian DA, Perri MG, Nexu AM, McKelvey WF, Shermer RL, Anton SD. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol. 2001;69(4):717-721. (Pubitemid 32803861)
11. Hernan WH, Brandle M, Zhang P, et al The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26(1):36-47. (Pubitemid 36928992)
12. Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health. 1988;78(11):1417-1421. (Pubitemid 18259678)
13. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
14. The Diabetes Prevention Program Research Group. Within-trial costeffectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26(9):2518-2523.
15. Avenell A, Broom J, Brown TJ, et al. Systematic review of the longterm effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8(21):155-162.
16. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26(2):304-321. (Pubitemid 38339022)
17. Herman WH, Hoerger TJ, Brandle M, et al Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323-332. (Pubitemid 40293405)
18. Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Prim Care Diabetes. 2012;6(2):109-121.
19. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Costeffectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30(10):2548-2552. (Pubitemid 47547791)
20. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143(4):251-264.
21. Russell LB. Preventing chronic disease: an important investment, but don't count on cost savings. Health Affairs. 2009;28(1):42-45.